Sentinel lymph node biopsy should be considered for clinically node-negative breast cancer regardless of BRCA1/2 mutation status

BACKGROUND: BRCA1/2 mutations lead to an elevated risk of breast cancer. None involved in whether BRCA1/2 mutation status will affect the first decision-making of sentinel lymph node (SLN) biopsy or not for clinically node-negative breast cancer. We retrospectively investigated whether BRCA1/2 mutat...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xin, Liu, Jia-Qi, Zhou, Yi-Dong, Xu, Ying, Chen, Chang, Wang, Xiang, Cao, Xi, Yao, Ru, Sun, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576024/
https://www.ncbi.nlm.nih.gov/pubmed/33241032
http://dx.doi.org/10.21037/atm-20-5996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576024/
https://www.ncbi.nlm.nih.gov/pubmed/33241032
http://dx.doi.org/10.21037/atm-20-5996

Ejemplares similares